BioNxt Solutions, Bayer, Palantir - AI is dominating the market at breathtaking speed and ensuring high returns

BioNxt Solutions - Partners with German pharma company for production site

The European market for thin-film drugs is estimated at around USD 5.18 billion. This market is expected to grow at a CAGR of 9.33% by 2027, reaching a volume of approximately USD 8.09 billion. This forecast covers the period from 2022 to 2027.

Thin-film drugs are, for example, transdermal patches or transdermal therapy systems placed on the skin to deliver active substances into the body. These patches consist of a thin layer coated with a controlled amount of the active ingredient.

BioNxt Solutions is a Canadian biotech company specializing in precisely this therapy niche. A special state-of-the-art coating and cutting machine has now been purchased for its German partner Vektor Pharma at their site in Baden-Württemberg, Germany, in order to further expand commercial production capacities at the facility there. The machines meet high European safety standards. Germany is known for its leading university institutions, research institutes and companies that continuously invest in developing new drugs, therapies and technologies.

For BioNxt Solutions, the advantages of transdermal therapy are clear. By placing them on the skin, thin-film drugs enable systemic absorption of the active ingredients, where they enter the bloodstream through the skin. This allows them to bypass the digestive tract and liver, which can lead to improved drug efficacy and reduced side effects. Thus, patient well-being is part of the Company's value creation.

Bayer - Consumer Health goes digital for seamless therapeutic pathways

Novel delivery mechanisms are currently also high on the agenda at Bayer AG. Since clinical studies need a certain amount of time to gain scientific evidence, the new business unit for precision medicine is being created in the Consumer Health division, merging digital technologies and consumer health products. In other words, a potential B2C solution that cleverly removes the group from potential regulatory traps that the therapy market otherwise entails.

The interdisciplinary executive squad at Bayer will focus on addressing unmet needs in its core categories by introducing new, evidence-based precision health products that enable seamless self-care. The group will work closely with start-ups and other players in the digital health space, developing Bayer's existing digital capabilities.

In the past, Bayer launched a start-up initiative with Grants4Apps, but this was more secondary to marketing than product innovation. Patricia Corsi, Chief Marketing, Digital and Information Officer at Consumer Health, explains the new business unit as follows: "Consumers are constantly looking for health solutions that go beyond traditional product formats such as pills or creams. As we meet their needs, we continue our journey to increase brand value and engagement with the people we serve while driving the digital transformation of our consumer health business."

Palantir - AIP Technology as a game changer for AI-powered platforms

Palantir has established itself as a leading player in the data analytics industry with extensive expertise in applying artificial intelligence to address complex data challenges. The Company works with clients such as the US National Security Agency (NSA), the Federal Bureau of Investigation (FBI) and the US Army. All of which manage highly sensitive data.

Palantir is now introducing its latest product, the Artificial Intelligence Platform - AIP. According to CEO Alex Karp, demand for AIP is like nothing he has seen in his 20 years at Palantir.

AIP is a platform that allows customers to use language models similar to ChatGPT within their on-premises computer systems with access to private data. Although tools like ChatGPT learn quickly, they are trained with very general data. The concept behind AIP is that the model accesses a company's entire data set to gain a deep understanding of the Company's operations.

The goal of AIP is to give clients a real-time representation of all the elements of a business while setting ground rules and guidelines for what data the models can access and what they can do with it.

While OpenAI is currently getting a lot of attention, a recently leaked memo from Google tells a different story about the dominance of artificial intelligence (AI). The memo claims that the open source community has "outpaced" both Google and OpenAI in the development of AI models and that proprietary models such as GPT-3 and Google Bard will ultimately offer no advantage.

Given this situation, Palantir COO Shyam Sankar believes that the long-term business value is not in AI development but in its application. Imagine an AIP for all the data from BioNxt or Bayer AG and their third-party applications - with real-time analysis. At a recent conference call, Alex Karp told investors that the Company's AI strategy is to simply "dominate the entire market."

BioNxt Solutions' collaboration with German pharmaceutical company Vektor Pharma creates an opportunity for the continued development and commercialization of key products in BioNxt's pipeline portfolio. In addition, there is the opportunity to undertake strategic contract research and development projects. For Bayer, as part of the trend towards self-care for everyday healthcare, people increasingly use digital tools to better understand their individual needs and make smarter decisions. According to David Evendon-Challis, Head of Research and Development and Chief Scientific Officer of Bayer's Consumer Health Division, Bayer is a global leader in core categories central to self-care, such as cardiovascular and digestive health, pain management and immunity. The Company plans to offer a wide range of precision health products and services to meet this need. Palantir is uniquely positioned with its AI developments as it is able to process complex and large datasets from government organizations with sensitive information, such as the CIA.** This knowledge puts Palantir at the forefront of AI companies, and it can roll out its services to private sector companies at any time.